CICC: Maintain MicroPort Medical (00853) 's "outperform industry" rating and lower the target price to HK $23.4

智通财经2022-09-02

Zhitong Finance APP learned that CICC released a research report stating that it maintains the "outperform industry" rating of MicroPort Medical (00853), lowers the net loss forecast attributable to the parent company in 2022/23 by US $24/55 million to US $31/290 million, and the target price drops 5% to HK $23.4, which is 42.9% upside from the current stock price. The company's 1H22 revenue was US $405 million, a year-on-year increase of 5.3%, and a year-on-year increase of 10.1% after excluding the impact of exchange rates. The loss attributable to equity shareholders expanded to US $198 million year-on-year, lower than the bank and market expectations. According to the report, Shanghai Medical Insurance Bureau will...

Web link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2264223331?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2022-09-02 08:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2264223331","market":"sh","top_or_hot":-1,"title":"CICC: Maintain MicroPort Medical (00853) 's \"outperform industry\" rating and lower the target price to HK $23.4","media":"智通财经","content":"<p><div>Zhitong Finance APP learned that CICC released a research report stating that it maintains the \"outperform industry\" rating of MicroPort Medical (00853), lowers the net loss forecast attributable to the parent company in 2022/23 by US $24/55 million to US $31/290 million, and the target price drops 5% to HK $23.4, which is 42.9% upside from the current stock price. The company's 1H22 revenue was US $405 million, a year-on-year increase of 5.3%, and a year-on-year increase of 10.1% after excluding the impact of exchange rates. The loss attributable to equity shareholders expanded to US $198 million year-on-year, lower than the bank and market expectations. According to the report, Shanghai Medical Insurance Bureau will...</p><p><a href=\"http://www.zhitongcaijing.com/content/detail/786574.html\">Web link</a></div></p>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CICC: Maintain MicroPort Medical (00853) 's \"outperform industry\" rating and lower the target price to HK $23.4</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCICC: Maintain MicroPort Medical (00853) 's \"outperform industry\" rating and lower the target price to HK $23.4\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2022-09-02 08:53</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div>Zhitong Finance APP learned that CICC released a research report stating that it maintains the \"outperform industry\" rating of MicroPort Medical (00853), lowers the net loss forecast attributable to the parent company in 2022/23 by US $24/55 million to US $31/290 million, and the target price drops 5% to HK $23.4, which is 42.9% upside from the current stock price. The company's 1H22 revenue was US $405 million, a year-on-year increase of 5.3%, and a year-on-year increase of 10.1% after excluding the impact of exchange rates. The loss attributable to equity shareholders expanded to US $198 million year-on-year, lower than the bank and market expectations. According to the report, Shanghai Medical Insurance Bureau will...</p><p><a href=\"http://www.zhitongcaijing.com/content/detail/786574.html\">Web link</a></div></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://www.zhitongcaijing.com/content/detail/786574.html\">智通财经</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00853","symbol_name":"微创医疗","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/786574.html","article_id":"2264223331","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2264223331","pubTimestamp":1662080038,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，中金发布研究报告称，维持微创医疗“跑赢行业”评级，下调2022/23年归母净亏损预测0.24/0.55亿美元至3.1/2.9亿美元，目标价降5%至23.4港元，较当前股价有42.9%的上行空间。公司1H22收入4.05亿美元，同比增长5.3%，剔除汇率影响后同比增长10.1%，权益股东应占亏损同比扩大至1.98亿美元，低于该行和市场预期。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"00853":"微创医疗"},"translate_title":"CICC: Maintain the target price of minimally invasive medical (00853) \"outperform the industry\" rating to HK $23.4","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00853":1},"content_text":"智通财经APP获悉，中金发布研究报告称，维持微创医疗(00853)“跑赢行业”评级，下调2022/23年归母净亏损预测0.24/0.55亿美元至3.1/2.9亿美元，目标价降5%至23.4港元，较当前股价有42.9%的上行空间。公司1H22收入4.05亿美元，同比增长5.3%，剔除汇率影响后同比增长10.1%，权益股东应占亏损同比扩大至1.98亿美元，低于该行和市场预期。报告中称，上海医保局5月将TAVR耗材纳入医保范围(报销75-80%);北京医保局7月公布创新器械的DRG除外支付办法;国家医保局8月在答复人大提议时表示正研究完善相关政策，指导各地及时将符合条件的创新医疗器械纳入医保支付范围。2022年以来，起搏器、冠脉药球和颅内弹簧圈集采结果趋于温和，脊柱、心脏电生理也根据具体情况制定合理分组竞价规则。该行认为政策端对真正具有技术创新和临床受益产品的支持日渐明晰，期待各类利好政策加速以TAVR和手术机器人为代表的国产创新器械放量，利好以微创为代表的平台型国产创新医疗器械企业。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2264223331"}